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Pten deletion from adult mouse hematopoietic cells
activates the PI3-kinase pathway, inducing hema-
topoietic stem cell (HSC) proliferation, HSC deple-
tion, and leukemogenesis. Pten is also mutated in
human leukemias, but rarely in early childhood
leukemias. We hypothesized that this reflects
developmental changes in PI3-kinase pathway
regulation. Here we show that Rictor deletion
prevents leukemogenesis and HSC depletion after
Pten deletion in adult mice, implicating mTORC2
activation in these processes. However, Rictor
deletion had little effect on the function of normal
HSCs. Moreover, Pten deletion from neonatal
HSCs did not activate the PI3-kinase pathway or
promote HSC proliferation, HSC depletion, or
leukemogenesis. Pten is therefore required in adult,
but not neonatal, HSCs to negatively regulate
mTORC2 signaling. This demonstrates that some
critical tumor suppressor mechanisms in adult cells
are not required by neonatal cells. Developmental
changes in key signaling pathways therefore confer
temporal changes upon stem cell self-renewal and
tumor suppressor mechanisms.
INTRODUCTION
Hematopoietic stem cells (HSCs) persist throughout life by
undergoing self-renewing divisions regulated by networks of
proto-oncogenes and tumor suppressors (He et al., 2009).
Mechanisms that promote HSC self-renewal are commonly
overactivated or ectopically activated in leukemia cells (Reya
et al., 2001). These self-renewal mechanisms are co-opted by
leukemia cells irrespective of whether they arise from HSCs or
from restricted progenitors (Krivtsov et al., 2006).Cell SHSC properties and self-renewal mechanisms change over
time. The transcription factor Sox17 is required for the mainte-
nance of fetal and neonatal, but not adult, HSCs (Kim et al.,
2007). Conversely, the epigenetic/transcriptional regulators
Bmi-1, Tel/Etv6, and Gfi-1 regulate the maintenance of post-
natal, but not fetal, HSCs (Lessard and Sauvageau, 2003; Park
et al., 2003; Hock et al., 2004a, 2004b). The temporal changes
in HSC self-renewal mechanisms raise the question of whether
the driver mutations that are competent to cause leukemia also
change over time.
Hematopoieticmalignancies occur throughout life and the inci-
dence of specific driver mutations varies with patient age, even
within the same subtype of leukemia (Downing and Shannon,
2002). Myeloid leukemias in young children are often driven by
translocations involving transcription factors (Downing and
Shannon, 2002). In contrast, myeloid leukemias in older children
and adults are much more likely to have mutations that activate
the PI3-kinase pathway, including Bcr-Abl and Flt3 internal
tandem duplications (Meshinchi et al., 2001; Zwaan et al., 2003;
Martelli et al., 2006; Kharas et al., 2008, 2010). These observa-
tions raise the question of whether age-dependent changes in
leukemia driver mutations occur because of developmental
changes in signaling mechanisms that regulate self-renewal.
The Pten tumor suppressor negatively regulates PI3-kinase
pathway signaling and is commonly inactivated in many cancers
(Di Cristofano and Pandolfi, 2000). Pten loss-of-function muta-
tions occur frequently in T-precursor ALL (T-ALL) andPten is inac-
tivated in some acute myeloid leukemias (AMLs) by mutations,
promoter methylation, or transcriptional repression (Dahia et al.,
1999; Gutierrez et al., 2009; Larson Gedman et al., 2009; Yoshimi
et al., 2011). While B-ALL usually presents in young children and
rarely involves Pten deletion (Mullighan et al., 2011), pediatric
T-ALL exhibits an older mean age of presentation (9–10 years
of age) (Smith et al., 1999; Clappier et al., 2007; Karrman et al.,
2009) and commonly involves Pten deletion or other mutations
that activate PI3-kinase pathway signaling (Gutierrez et al., 2009).
One possibility is that PI3-kinase pathway regulation changes
over time in hematopoietic cells. Pten deletion from hematopoi-
etic cells in adult mice leads to the development of T-ALL (Yilmaztem Cell 11, 415–428, September 7, 2012 ª2012 Elsevier Inc. 415
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A c-kit+ enriched cells Figure 1. HSCs that Proliferate under Phys-
iological Conditions Exhibit Little or No
Increase in AKT Phosphorylation
(A) Representative flow cytometry plots for HSC
cell cycle analysis.
(B) The percentage of CD150+CD48LSK HSCs in
S/G2/M phases of the cell cycle from E14.5 fetal
(n = 3), P14 neonatal (n = 3), 8-week-old adult
(n = 6), 8-week-old pIpC-treated Mx1-Cre; Ptenfl/fl
(n = 3), and cyclophosphamide/G-CSF-treated
adult mice (n = 3). All comparisons are relative to 8-
week-old adult mice (*p < 0.05; **p < 0.01; ***p <
0.001). Error bars reflect standard deviation and
p values were calculated by two-tail Student’s
t test.
(C) CD48LSK HSCs/MPPs have a similar cell
cycle distribution to that of HSCs.
(D) PI3-kinase pathway components in HSCs/
MPPs (30,000 CD48LSK cells per lane).
(E) AKT phosphorylation in fetal HSCs in G0/G1
versus S/G2/M phases of the cell cycle (10,000
cells per lane).
(F) Adult GMP myeloid restricted progenitors, but
not HSCs/MPPs, exhibited increased AKT and S6
phosphorylation after cyclophosphamide/2 days
G-CSF treatment (20,000 cells per lane).
(G) Even after cyclophosphamide and 4 days of
G-CSF,mobilizedspleenHSCs/MPPs (20,000cells
per lane) did not exhibit increased AKT phosphor-
ylation relative to normal adult HSCs/MPPs.
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Temporal Changes in Signaling in Stem Cellset al., 2006; Zhang et al., 2006; Guo et al., 2008; Lee et al., 2010).
Pten deletion from adult mouse HSCs causes these cells to go
into cycle and to be depleted by a tumor suppressor response
induced by hyperactivation of mTOR (Yilmaz et al., 2006; Lee
et al., 2010). Both leukemogenesis and HSC depletion after
Pten deletion can be rescued by treating mice with rapamycin
(Yilmaz et al., 2006). This suggests that these phenotypes are
mediated by RAPTOR/mTORC1 activation; however, rapamycin
can also indirectly inhibit RICTOR/mTORC2 signaling (Sarbas-
sov et al., 2006), and mTORC1 activation is influenced by
mTORC2 signaling (Guertin and Sabatini, 2007; Guertin et al.,
2009). Consequently, the relative contribution of mTORC1 and
mTORC2 to these phenotypes is uncertain. It also remains
unclear whether Pten deletion drives HSCs into cycle by acti-
vating physiological mechanisms that induce HSC division or
by activating mechanisms that do not normally regulate HSC
division.
To address these questions we evaluated PTEN function,
RICTOR/mTORC2 function, and PI3-kinase pathway activation
in fetal, neonatal, and adult HSCs. AKT phosphorylation did
not detectably increase in HSCs that divided under physiological
conditions. Consistent with this, Rictor deletion had little effect
on HSC frequency or function. However, Rictor deletion largely
rescued the increased AKT phosphorylation, HSC depletion,
and leukemogenesis observed after Pten deletion from adult
HSCs. This suggests that Pten deletion promotes HSC prolifer-
ation by activating signaling pathways that have a limited role416 Cell Stem Cell 11, 415–428, September 7, 2012 ª2012 Elsevier Inc.in HSC self-renewal under physiological
conditions. The observation that Pten
deletion provides no selective advantageto neonatal hematopoietic cells may explain why Ptenmutations
are rare in leukemias that affect young children. Temporal
changes in the signaling mechanisms that regulate self-renewal
lead to temporal changes in leukemogenic mechanisms.
RESULTS
Normal HSC Proliferation Is Not Associated with
Increased AKT Phosphorylation
HSCs divide rapidly during fetal and neonatal development (Mor-
rison et al., 1995) and after cyclophosphamide/G-CSF treatment
(Morrison et al., 1997). We compared the cell cycle status of
HSCs (CD150+CD48LinSca-1+c-kit+) isolated from embryonic
day (E)14.5 fetal mice, postnatal day (P)14 neonatal mice, 8-
week-old adult mice, andmice that were treated with cyclophos-
phamide and two daily doses of G-CSF (Figures 1A and 1B;
Table S1 available online). We also administered poly-inosine:p-
oly-cytosine (pIpC) to Mx1-Cre; Ptenfl/fl mice 6 weeks after birth
and isolated HSCs for cell cycle analysis at 8 weeks after birth.
The fraction of HSCs in S/G2/M phases of the cell cycle
decreased significantly from E14.5 to P14 to 8 weeks after birth
(Figure 1B). The frequency of HSCs in S/G2/M phases of the cell
cycle after cyclophosphamide/G-CSF treatment was signifi-
cantly greater than after Pten deletion (Figure 1B).
To assess whether AKT activation correlates with the
frequency of HSCs/MPPs in cycle, we compared AKT phosphor-
ylation between CD48LineageSca-1+c-Kit+ (CD48LSK)
Cell Stem Cell
Temporal Changes in Signaling in Stem CellsHSCs/MPPs (Kiel et al., 2005; Kim et al., 2006) from E14.5 fetal
liver, P14 bone marrow, 8-week-old adult wild-type bone
marrow, and 8-week-old bone marrow after Pten deletion from
Mx1-Cre; Ptenfl/fl mice. The cell cycle distribution in the HSC/
MPP population was similar to that of highly purified HSCs (Fig-
ure 1C), consistent with prior studies (Foudi et al., 2009). As ex-
pected, AKT and S6 were more highly phosphorylated in Pten-
deficient adult HSCs/MPPs as compared to wild-type adult
HSCs/MPPs (Figure 1D). However, phosphorylated AKT levels
were lower in fetal and neonatal HSCs/MPPs compared to
normal adult HSCs/MPPs (Figure 1D), even though fetal and
neonatal HSCs/MPPs were more mitotically active (Figure 1C).
Levels of phosphorylated S6 were higher in fetal HSCs/MPPs
but lower in neonatal HSCs/MPPs as compared to adult HSCs/
MPPs (Figure 1D). Phosphorylated AMPK and GSK3b levels
did not significantly differ between fetal, neonatal, and adult
HSCs/MPPs. Fetal HSCs/MPPs in G0/G1 versus S/G2/M
phases of the cell cycle exhibited similar levels of AKT phosphor-
ylation (Figure 1E).
We next evaluated AKT and S6 phosphorylation in sorted
HSCs/MPPs from the bone marrow of untreated or cyclophos-
phamide/G-CSF-treated 8-week-old adult mice. After cyclo-
phosphamide and 2 days of G-CSF, HSCs/MPPs did not exhibit
increased AKT or S6 phosphorylation (Figure 1F) despite the high
percentage of cells in S/G2/M (Figures 1B and 1C). Granulocyte-
monocyte progenitors (Lineagec-kit+Sca-1CD34+CD16/32+
cells; GMPs) from the same mice did have higher levels of phos-
phorylated AKT and S6 after cyclophosphamide/G-CSF treat-
ment (Figure 1F). CD48LSK cells were also harvested from
the spleens of mice treated with cyclophosphamide and
4 days of G-CSF. HSCs/MPPs from these mice still did not
exhibit increased AKT phosphorylation relative to normal adult
HSCs, though an increase in 4EBP phosphorylation was
observed (Figure 1G). Rapidly dividing HSCs therefore exhibit
little or no increase in AKT phosphorylation relative to quiescent
adult HSCs.
Pten Is Required by Adult, but Not Neonatal, HSCs
To determine whether Pten regulates neonatal HSCs, we
induced Cre in Mx1-Cre; Ptenfl/fl mice by administering a single
subcutaneous dose of pIpC 2 days after birth, resulting in
complete Pten deletion in HSCs (Figure S1 available online).
Bromo-deoxyuridine (BrdU) was then administered for 24 hr
before the mice were sacrificed (Figures 2A and 2B). The overall
proliferation of unfractionated bone marrow cells at 2, 3, 4, and
5 weeks after birth was not affected by Pten deletion (Figure 2A).
The overall rate of BrdU incorporation into control CD150+
CD48LinSca-1+c-Kit+ HSCs declined from 2 (25% ± 8.5%)
to 5 (10% ± 6.8%) weeks after birth as HSCs made the transition
to a more slowly dividing adult phenotype (Figure 2B). Pten dele-
tion had no effect on BrdU incorporation into HSCs at 2 weeks
after birth, but Pten-deficient HSCs showed a trend toward
increasedBrdU incorporation relative to control HSCs at 3weeks
after birth, and the effect was statistically significant at 4 and
5 weeks after birth (Figure 2B).
To determine whether Pten deletion mobilizes neonatal HSCs,
we administered pIpC to 2-day-old neonatal mice or to 6-week-
old adult mice, thenmeasured the number of HSCs per spleen at
2, 4, and 8 weeks after birth (Figure 2C). We observed a >40-foldCell Sincrease in the number of HSCs in the spleens of 8-week-old
adult mice (2 weeks after Pten deletion; Figure 2C). In contrast,
Pten deletion had no effect on the number of HSCs in the spleen
of 2-week-old mice and only modestly (but significantly)
increased the number of HSCs in the spleens of 4-week-old
mice (Figure 2C).We also did not observe any effect ofPten dele-
tion on the overall proliferation of splenocytes until 4 weeks after
birth (Figure 2D). Pten deletion therefore does not lead to
increased HSC proliferation or mobilization until around 4 weeks
after birth.
We compared the reconstituting capacity of HSCs from
neonatal and adult mice after Pten deletion at 2 days or 6 weeks
after birth. We transplanted 10 CD45.2+ CD150+CD48Lin
Sca-1+c-kit+ HSCs from donor mice of each age and genotype
into irradiated CD45.1+ mice along with 300,000 wild-type
CD45.1+ bone marrow cells. Control adult (Figures 2E and 2F)
and neonatal (Figures 2G and 2H)HSCs gave long-termmultiline-
age reconstitution by myeloid and lymphoid cells in all recipient
mice. Pten-deficient adult HSCs gave only transient multilineage
reconstitution that lasted less than 16weeks after transplantation
in all recipient mice (Figures 2E and 2F). Pten-deficient neonatal
HSCs gave long-term multilineage reconstitution in most recipi-
ents that lasted at least 16 weeks after transplantation, but none
of these recipientsweremultilineage reconstitutedafter 24weeks
(Figures 2G and 2H). Pten-deficient neonatal HSCs therefore
retained the capacity to give long-term multilineage reconstitu-
tion, suggesting that they did not initially depend upon Pten.
The ultimate depletion of Pten-deficient neonatal HSCs 16 to
24 weeks after transplantation presumably reflects their matura-
tion into adult HSCs as fetal HSCs acquire an adult phenotype
after transplantation into adult mice (Figures S1B and S1C).
PTEN Prevents Leukemia in Adult, but Not Neonatal,
Mice
To test whether Pten deletion causes neoplastic proliferation in
neonatal mice, we treated littermate control and Mx1-Cre;
Ptenfl/fl mice with pIpC at 2 days or 6 weeks after birth. Two
weeks after pIpC treatment was performed, we observed a
3-fold increase in spleens’ cellularity and weight in adult, but
not neonatal, Pten-deleted mice (Figures 2I and 2J). We also
observed histological signs of myeloproliferative disorder in
adult, but not neonatal, spleen after Pten deletion. Two weeks
after Pten deletion in adult mice, spleens exhibited a substantial
expansion of the red pulp and extramedullary hematopoiesis
consistent with myeloproliferative disorder (Figures 2K and 2L).
Two weeks after Pten deletion in neonatal mice, spleens had
qualitatively fewer follicles than spleens from littermate controls
(data not shown), consistent with the reduction in B cells in
neonatal Pten-deficient mice (Figures 4J and 4K). Otherwise,
the histological appearance of neonatal Pten-deficient and
control spleens was indistinguishable (Figures 2M and 2N).
Pten is therefore not required to prevent myeloproliferative
disorder in neonatal mice.
When Pten is deleted from young adult mice they succumb to
T-ALL by 12 weeks after Cre induction (Yilmaz et al., 2006; Lee
et al., 2010). This latency period makes it difficult to test whether
Pten deletion is leukemogenic in neonatal mice because they
would mature into adults before the onset of leukemia; therefore,
to test whether Pten is a tumor suppressor in neonatal mice, wetem Cell 11, 415–428, September 7, 2012 ª2012 Elsevier Inc. 417
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Figure 2. Pten Is Not Required to Regulate HSC Maintenance, Proliferation, or Function in Neonatal Mice
(A and B) BrdU incorporation in bone marrow cells and HSCs (24 hr pulse; three or four independent experiments; *p < 0.05).
(C) The numbers of HSCs in the spleens of mice that received pIpC 2 days after birth then were then analyzed at 2 or 4 weeks after birth, or those that received
pIpC at 6 weeks after birth were then analyzed 8 weeks after birth (n = 4–10 mice per genotype, *p < 0.05; ***p < 0.0001).
(D) Splenocyte BrdU incorporation (24 hr BrdU pulse; n = 3–4 mice per time point and genotype; **p < 0.01).
(E–H) Long-term competitive repopulation assays with 10 wild-type or Pten-deficient (Pten D/D) adult or neonatal HSCs (n = 7–10 recipients/age/genotype;
*p < 0.05; **p < 0.01; ***p < 0.001). The threshold at which donor cells could be detected above background (in negative control mice, 0.5%) is indicated by the
black line.
(I and J) Spleen cellularity (I) and mass (J) for Pten-deleted adult and neonatalMx1-Cre; Ptenfl/fl mice as well as littermate controls 2 weeks after pIpC treatment
(n = 10–13 mice/age/genotype; *p < 0.05; ***p < 1 3 1010).
(K–N) Representative low power (403) spleen sections stained with H&E fromwild-type adult (K), Pten-deleted adult (L), wild-type neonatal (M), and Pten-deleted
neonatal (N) mice.
For all panels, error bars reflect standard deviation and p values were calculated by two-tailed Student’s t test.
Cell Stem Cell
Temporal Changes in Signaling in Stem Cellsdeleted Pten from p53-deficient mice. In adult mice this greatly
accelerates leukemogenesis (Lee et al., 2010). This allowed us
to test whether neonatal mice are immediately competent to
develop leukemia after Pten deletion or whether an adult devel-
opmental context is required.We administered pIpC toMx1-Cre;
Ptenfl/fl; p53/ mice and littermate controls (that lacked Mx1-
Cre) at 2 days or 6 weeks after birth. By 20 days after pIpC treat-
ment, all adult Mx1-Cre; Ptenfl/fl; p53/ mice died with signs of
leukemia (Figure 3A). Control p53/ or p53+/ adult mice that re-
tained Pten all survived for at least 100 days with no evidence of
hematopoietic neoplasms (Figures 3A and 3B). All moribund
adult Mx1-Cre; Ptenfl/fl; p53/ mice had large mediastinal
masses and infiltrative precursor T-ALL (Figures 3E–3H). Adult418 Cell Stem Cell 11, 415–428, September 7, 2012 ª2012 Elsevier IMx1-Cre; Ptenfl/fl; p53/ mice therefore developed T-ALL and
died within 20 days of pIpC.
At 21 days after pIpC treatment, when all of the adultMx1-Cre;
Ptenfl/fl; p53/ mice were dead, none of the neonatal Mx1-Cre;
Ptenfl/fl; p53/ mice that had been treated with pIpC at 2 days
of age showed any signs of illness (Figure 3A). These mice did
not die until 44 to 60 days after pIpC treatment, when they were
6- to 8-week-old adults (Figure 3A). Indeed, theMx1-Cre; Ptenfl/fl;
p53/ mice died at the same time after birth irrespective of
whether pIpC was administered at 2 days or 6 weeks after birth
(Figure 3C). When neonatal Mx1-Cre; Ptenfl/fl; p53/ mice
were sacrificed at 17 days after pIpC treatment (a time point at
which all adultMx1-Cre; Ptenfl/fl; p53/mice showed clear signsnc.
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(A–D) Kaplan-Meier survival curves for Mx1-Cre;
Ptenfl/fl; p53/ (A and C; n = 6–8 mice/treatment)
and Mx1-Cre; Ptenfl/fl; p53+/ mice (B and D; n =
7–9 mice/treatment) following pIpC treatment at
2 days (neonatal) or 6 weeks (adult) after birth.
Survival times are shown either as the time
following pIpC treatment (A and B) or as time after
birth (C and D). Ptenmutant mice that were treated
neonatally with pIpC survived significantly longer
after pIpC treatment thanmice treated with pIpC as
adults (***p < 0.001 by the log rank test).
(E–H) Spleen and thymus sections from adult mice
that were treated with pIpC at 6 weeks after birth
and sacrificed for analysis 17 days later (403, inset
4003).
(I–L) Spleen and thymus sections from neonatal
mice treated with pIpC 2 days after birth and
sacrificed for analysis 17 days later (403).
(M–P) Spleen and thymus sections from mice that
received pIpC 2 days after birth and developed
T-ALL as adults (403, inset 4003).
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Temporal Changes in Signaling in Stem Cellsof T-ALL), none of the neonatally treated mice showed any signs
of illness or leukemia: they had normal thymus and spleen
histology (Figures 3I–3L); however, when these mice became ill
approximately 50days after pIpC treatment, they had largemedi-
astinalmasses and infiltrative T-ALL (Figures 3M–3P). The obser-
vation that Mx1-Cre; Ptenfl/fl; p53/ mice succumbed to
leukemia at the same time, irrespective of whether Pten was
deleted 2 days or 6 weeks after birth (Figure 3C), demonstrates
that an adult developmental context is required for leukemia after
Pten deletion. We performed similar experiments in mice with
a p53 heterozygous background and obtained similar results
(Figures 3B and 3D).
Pten Deletion Increases PI3-Kinase Pathway Activation
in Adult, but Not Neonatal, HSCs
To test whether Pten is required in neonatal HSCs to regulate
PI3-kinase pathway signaling, we administered pIpC toCell Stem Cell 11, 415–428, SMx1-Cre; Ptenfl/fl mice or littermate
controls at 2 days or 6 weeks after birth.
We isolated CD48LSK cells 2 weeks later
and performed western blots. The total
levels of PTEN, AKT, S6, and GSK3b
were similar in neonatal and adult HSCs/
MPPs from control mice (Figures 4A and
4B). In both the neonatal and adult
HSCs/MPPs, we observed a complete
loss of PTEN protein from Mx1-Cre;
Ptenfl/fl cells (Figures 4A and 4B). In adult
HSCs/MPPs, Pten deletion increased the
phosphorylation of AKT, S6, and GSK3b,
but not MAPK or AMPK (Figures 4A and
4B). In neonatal HSCs/MPPs, Pten dele-
tion had little or no affect on AKT, S6,
and GSK3b phosphorylation (Figures 4A
and 4B). Pten deletion did not increaseAKT phosphorylation in HSCs/MPPs until 3 to 4 weeks after birth
(Figure 4C), the same time we began to observe increased HSC
proliferation after Pten deletion (Figure 2B).
To determine whether neonatal HSCs/MPPs are capable of
activating the PI3-kinase pathway, we incubated neonatal or
adult HSCs/MPPs from control and Mx1-Cre; Ptenfl/fl mice in
culture with 2% fetal bovine serum at 37C for 30min. In contrast
to uncultured neonatal Pten-deficient HSCs/MPPs, phosphory-
lated AKT was present at comparable levels in neonatal versus
adult Pten-deficient HSCs/MPPs (Figure 4D). Neonatal HSCs
are therefore capable of phosphorylating AKT when exposed
to serum in culture and PTEN negatively regulates this process.
Several PI3K pathway proteins, including AKT, S6, RICTOR,
mTOR, RAPTOR, and SHIP1, are expressed at similar levels in
neonatal and adult HSCs (Figures 4A, 4B, and 4E). Phosphoryla-
tion of mTOR at Ser2481, which reflects mTORC2 function
(Copp et al., 2009), was also similar in neonatal and adulteptember 7, 2012 ª2012 Elsevier Inc. 419
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Figure 4. Neonatal HSCs Do Not Require PTEN to Negatively Regulate AKT Phosphorylation by mTORC2 In Vivo
(A) Western blots were performed on 30,000 wild-type or Pten-deficient CD48LSK cells isolated from adult and neonatal mice. After Pten deletion AKT and S6
phosphorylation increased in adult HSCs/MPPs but little increase was observed in neonatal HSCs/MPPs.
(B) AKT and GSK3b phosphorylation increased in adult, but not neonatal, HSCs/MPPs after Pten deletion.
(C) AKT phosphorylation in 20,000 HSCs/MPPs from 3- and 4-week-old control and Pten-deficient mice.
(D) HSCs/MPPs from adult and neonatal mice were incubated in Iscove’s medium with 2% fetal bovine serum for 30 min.
(E) The expression levels of several PI3-kinase pathway components were similar in adult and neonatal HSCs/MPPs (30,000 cells per lane).
(F) Phosphorylation of mTOR at Ser2481 was not different between adult and neonatal HSCs/MPPs.
(G) AKT phosphorylation in 20,000 wild-type or Pten-deficient CD48LSK cells (HSCs/MPPs), CD48+LSK cells (restricted progenitors), or bonemarrow cells from
adult or neonatal mice.
(H and I) AKT and S6 phosphorylation in neonatal and adult, control and Pten-deficient LMPPs (H), GMPs (H), and CD4+CD8+ thymocytes (I).
(J and K) In both adult and neonatal mice, Pten deletion significantly reducedB cell frequencies and significantly increasedmyeloid cell frequencies (n = 6–7mice/
age/genotype; **p < 0.01; ***p < 0.001). Error bars always represent standard deviation.
(L) pIpC treatment of Mx1-Cre; Rictorfl/fl mice eliminated RICTOR expression by LSK cells.
(M and N) Rictor deletion reduced AKT Ser473 phosphorylation in CD48LSK cells (M), and had similar effects to Torin1 treatment with respect to AKT phos-
phorylation at Ser473, but not with respect to S6 phosphorylation (N).
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Temporal Changes in Signaling in Stem CellsHSCs/MPPs (Figure 4F). A number of other gene products
known to regulate the PI3-kinase pathway were expressed at
similar levels in neonatal and adult HSCs by quantitative RT-
PCR (Figure S2A). Neonatal HSCs/MPPs are therefore capable
of activating the PI3-kinase pathway, but PTEN is not required
in neonatal HSCs/MPPs in vivo to negatively regulate pathway
activation.
Neonatal restricted progenitors (CD48+LSK cells) and unfrac-
tionated bonemarrow cells did exhibit increased AKT phosphor-
ylation following Pten deletion (Figure 4G). Pten deletion also
increased AKT and S6 phosphorylation in lymphoid primed mul-
tipotent progenitors (Lineagec-kit+Sca-1+CD34+FLT3+ cells;
LMPPs) and GMPs from neonatal and adult mice (Figure 4H).
In contrast, adult CD4+CD8+ thymocytes had much higher levels
of AKT and S6 phosphorylation after Pten deletion than neonatal
CD4+CD8+ thymocytes (Figure 4I). As in prior studies (Yilmaz
et al., 2006; Zhang et al., 2006), we observed an increase in mye-
lopoiesis and a decrease in B lymphopoiesis in adult bone
marrow after Pten deletion. We also observed an increase in
myelopoiesis and a decrease in B lymphopoiesis in the bone
marrow and spleen of neonatal mice after Pten deletion (Figures
4J and 4K). These data demonstrate that many restricted hema-
topoietic progenitors in neonatal mice depend upon PTEN to
regulate cellular signaling and function, just as observed in adult
mice, but that HSCs and T lineage progenitors undergo
a temporal change in their dependence upon PTEN between
the neonatal and adult stages.
To further explore the differences in PI3-kinase pathway regu-
lation between neonatal and adult HSCs, we compared the gene
expression profiles of P14 neonatal HSCs and 8-week-old adult
HSCs from wild-type mice. We identified 14 genes that were
significantly more highly expressed in neonatal HSCs, and 21
genes that were significantly more highly expressed in adult
HSCs (Table S2; fold change >2.0). Ten of these genes could
potentially regulate PI3-kinase pathway signaling based on prior
studies. The differential expression of eight of these genes was
confirmed by quantitative RT-PCR (Figure S2B, Table S3). For
example, Bank1 was expressed more highly in neonatal relative
to adult HSCs (Figure S2B) and is known to negatively regulate
AKT phosphorylation (Aiba et al., 2006). This provides candidate
genes that could potentially explain the difference in PTEN
dependence between neonatal and adult HSCs, but gene-tar-
geted mice will have to be generated to functionally test these
hypotheses.
Rictor Deletion Reduces AKT Phosphorylation in
Primitive Hematopoietic Progenitors
We next assessed the mechanisms by which Pten deletion
promotes HSC depletion and leukemogenesis in adult mice.
Pten deletion can activate both mTORC1 and mTORC2 (Guertin
and Sabatini, 2007); however, mTORC1 promotes proliferation
by phosphorylating S6 kinase and 4EBP1 while mTORC2 phos-
phorylates AKT at Ser473 (Guertin et al., 2006; Guertin and Sa-
batini, 2007). Since increased AKT phosphorylation at Ser473
distinguished Pten-deficient HSCs from HSCs that were dividing
under physiological conditions (Figure 1C), we tested whether
the effects of Pten deficiency were mediated by increased
mTORC2 activation. We generated a floxed allele that allowed
us to conditionally delete Rictor (Figure S3), a key componentCell Sof themTORC2 complex (Guertin et al., 2006), andwe generated
Mx1-Cre; Rictorfl/fl mice. We administered pIpC 6 weeks after
birth and observed an almost complete loss of RICTOR protein
fromMx1-Cre; Rictorfl/fl LSK cells, but mTORwas still expressed
(Figure 4L). We confirmed that both Rictor alleles were recom-
bined in all HSCs tested (Figure S4A).
To determine whether Rictor deletion attenuates AKT phos-
phorylation in HSCs/MPPs, we administered pIpC to control,
Mx1-Cre; Ptenfl/fl, Mx1-Cre; Rictorfl/fl, and Mx1-Cre; Ptenfl/fl;
Rictorfl/fl mice 6 weeks after birth. As expected, Pten deletion
increased AKT phosphorylation at Ser473 (Figure 4M). Rictor
deletion substantially reduced AKT Ser473 phosphorylation in
HSCs/MPPs, to levels lower than observed in control HSCs/
MPPs, even when Pten and Rictor were simultaneously deleted
(Figure 4M). This result is consistent with the expectation that
Rictor deletion reduces mTORC2 function.
To further evaluate RICTOR regulation of the PI3-kinase
pathway, we harvested LSK cells from 8-week-old control,
Mx1-Cre; Ptenfl/fl, Mx1-Cre; Rictorfl/fl, and Mx1-Cre; Ptenfl/fl;
Rictorfl/fl mice, 2 weeks after pIpC treatment. These cells were
incubated for 30 min in Iscove’s medium + 2% fetal bovine
serum before being harvested for western blotting. In parallel,
control and Pten-deficient LSK cells were incubated with
250 nM Torin1, an active site inhibitor of mTOR that inhibits
both mTORC1 and mTORC2 kinase activity (Thoreen et al.,
2009). Pten deletion increased AKT phosphorylation, and Rictor
deletion or Torin1 treatment eliminated AKT phosphorylation,
both in wild-type and Pten-deficient LSK cells (Figure 4N). We
also observed reduced AKT phosphorylation at Thr308 in
Mx1-Cre; Ptenfl/fl; Rictorfl/fl LSK cells relative to Mx1-Cre;
Ptenfl/fl LSK cells, and Torin1 treatment completely blocked
AKT phosphorylation at Thr308 even though this site is not
thought to be an mTORC1 or mTORC2 substrate (Figure 4N).
A similar decrease in Thr308 phosphorylation was previously
observed in Rictor-deficient prostate epithelium (Guertin et al.,
2009). These results confirm that Rictor deletion reduces
mTORC2 function and AKT phosphorylation in primitive hema-
topoietic progenitors.
Rictor Is Not Necessary for HSC Maintenance in
Neonatal or Adult Mice
To test if RICTOR is required by hematopoietic cells, we
analyzed Vav-Cre; Rictorfl/fl mice and Mx1-Cre; Rictorfl/fl mice.
Vav-Cre expresses in HSCs during early embryonic develop-
ment (de Boer et al., 2003). Vav-Cre; Rictorfl/fl mice were born
at Mendelian ratios and they matured to adulthood without any
gross abnormalities (data not shown). We did not observe signif-
icant differences in bone marrow cellularity, spleen cellularity,
spleen weight, or thymus weight between Vav-Cre; Rictorfl/fl
neonatal mice and littermate controls 14 days after birth (Figures
S4C and S4D). The frequency and absolute number of HSCs in
the bonemarrow of Vav-Cre; Rictorfl/fl neonatal mice was slightly
but significantly elevated relative to littermate controls (Figure 5A;
Figure S4E). We also deleted Rictor 2 days after birth by admin-
istering a single dose of pIpC to Mx1-Cre; Rictorfl/fl mice to
achieve complete recombination of the Rictorfl alleles (Fig-
ure S4B). At P14 we did not observe significant differences in
the frequency or absolute number of bone marrow HSCs
between Mx1-Cre; Rictorfl/fl mice and littermate controlstem Cell 11, 415–428, September 7, 2012 ª2012 Elsevier Inc. 421
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Figure 5. Rictor Deletion Had Only Modest
Effects on HSC Frequency and Function
(A) Vav-Cre-mediated Rictor deletion in fetal HSCs
slightly but significantly increased HSC numbers in
P14 mice (n = 5–7 mice per genotype, *p < 0.05).
Mx1-Cre-mediated Rictor deletion at P2 did not
significantly affect HSC numbers at P14.
(B and C) Vav-Cre or neonatal Mx1-Cre-mediated
Rictor deletion did not affect cell cycle distribution
(B) or BrdU incorporation (C) in HSCs at P14.
(D–F) Deletion of Rictor in 6-week-old adult Mx1-
Cre;Rictorfl/fl mice did not significantly affect
bone marrow cellularity (D), HSC frequency (E),
or absolute HSC number (F) when analyzed
18–24 weeks after pIpC treatment. However, MPP
frequency (E) and MPP numbers (F) were reduced
in Rictor-deleted mice relative to control mice
(n = 5–7 mice per genotype, ***p < 0.001).
(G–K) When 300,000 control or Rictor-deficient
CD45.2 bone marrow cells were transplanted
along with 300,000 CD45.1 wild-type bone
marrow cells into irradiated mice, recipients of
Rictor-deficient bone marrow were always long-
term multilineage reconstituted by donor cells but
levels of donor cell reconstitution were sometimes
significantly lower than in recipients of control cells
(n = 11–14 recipients per genotype, *p < 0.05; **p <
0.01; ***p < 0.001).
(L) The frequencies of donor HSCs andMPPs were
similar in primary recipients of control and Rictor-
deficient bone marrow cells (n = 11–14 per geno-
type).
(M and N) Secondary recipients of Rictor-deficient
and control bone marrow cells exhibited similar
levels of long-term multilineage reconstitution (n =
15 recipients per genotype).
Error bars reflect standard deviation and p values
were calculated by two-tailed Student’s t tests.
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Temporal Changes in Signaling in Stem Cells(Figure 5A; Figure S4E). Rictor is therefore not necessary for the
formation of HSCs or for fetal/neonatal hematopoiesis.
To determine whether Rictor regulates the proliferation of
neonatal HSCs, we evaluated the cell cycle status of HSCs iso-
lated at P14 from Vav-Cre; Rictorfl/fl mice andMx1-Cre; Rictorfl/fl
mice that received pIpC at P2. We did not observe significant
differences between control and Rictor-deficient HSCs in the
frequency of HSCs in S/G2/M phases of the cell cycle in either
genetic background (Figure 5B). We also observed no signifi-
cant difference in the BrdU incorporation rate of Rictor-defi-
cient and control HSCs (Figure 5C). Rictor is therefore not
required to regulate the maintenance or cell cycle of neonatal
HSCs.
To determine whether Rictor regulates adult hematopoiesis
or HSC function, we administered pIpC to adult Mx1-Cre;422 Cell Stem Cell 11, 415–428, September 7, 2012 ª2012 Elsevier Inc.Rictorfl/fl mice and littermate controls
6 weeks after birth. These mice were
observed for 18–24 weeks following
pIpC treatment and they did not develop
any overt signs of illness (data not
shown). After the observation period,
we detected a small, but significant,
decrease in white blood cell counts inRictor-deleted mice (Figure S4F), but red blood cell counts (Fig-
ure S4G), platelet counts (Figure S4H), and thymus cellularity
(Figure S4I) were not significantly affected by Rictor deletion.
We observed a trend toward reduced spleen cellularity in
multiple experiments but the effects were not statistically signif-
icant (Figure S4L). We also observed no significant difference in
bone marrow cellularity, HSC frequency, or absolute HSC
numbers (Figures 5D–5F). We did observe a significant reduc-
tion in the frequency of MPPs (CD150CD48LSK) after Rictor
deletion (Figures 5E and 5F). Rictor is therefore not required for
the maintenance of adult HSCs, but RICTOR may regulate
MPPs.
Rictor-deficient bone marrow cells gave long-term multiline-
age reconstitution of all recipient mice for at least 16 weeks
after transplantation (Figures 5G–5K). We observed significantly
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Figure 6. Rictor Is Necessary for Increased
HSC Proliferation, HSC Mobilization, and
HSC Depletion following Pten Deletion
(A and B) Rapamycin did not inhibit AKT phosphor-
ylation after 7 days in vivo (A) or 30 min in vitro (B).
(C) The percentage of HSCs in S/G2/M phases of
the cell cycle in control, Mx1-Cre; Rictorfl/fl (Ric-
torD/D),Mx1-Cre; Ptenfl/fl (PtenD/D), andMx1-Cre;
Ptenfl/fl; Rictorfl/fl (PtenD/D;RictorD/D)mice,with or
without 7 days of rapamycin treatment, 2 weeks
after pIpC treatment (n = 3–10 mice per genotype
and treatment).
(D) Rictor deletion, but not rapamycin treatment,
significantly reduced HSC mobilization to the
spleen following Pten deletion (n = 8–9 mice/
genotype).
(E and F) Rapamycin treatment, but not Rictor
deletion, increased bonemarrowHSC numbers (E)
and reduced HSC mobilization to the spleen
following cyclophosphamide/G-CSF treatment (F;
n = 5 mice/treatment).
(G–K) Ten CD45.2+ donor HSCs from Pten-defi-
cient mice failed to give long-term multilineage
reconstitution in irradiated mice. Rictor-deficient
HSCsgave long-termmultilineage reconstitution in
3 of 12 recipient mice, but levels of donor cell
reconstitution were generally lower than observed
from control HSCs. Pten; Rictor compound-defi-
cient HSCs were able to give long-term multi-
lineage reconstitution in nearly all irradiatedmice at
levels similar to those of control HSCs, with the
exception of the B cell lineage (I) (n = 12–16 mice/
genotype).
(L–P) Following secondary transplantation, Rictor-
deficient and Pten; Rictor compound-deficient
donor cells gave long-term multilineage reconsti-
tution of nearly all secondary recipient mice (n = 9–
22 mice/genotype).
Error bars represent standard deviation and
p values were calculated by two-tailed Student’s
t tests: *p < 0.05; **p < 0.01; ***p < 0.001; N.S., not
significant (p > 0.05).
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Temporal Changes in Signaling in Stem Cellsreduced levels of donor lymphocyte reconstitution in recipients
of Rictor-deficient bone marrow cells over the first 12 weeks
after transplantation, but this difference was not significant
by 16 weeks after transplantation (Figures 5I and 5J). We did
not observe any differences in the frequency of donor HSCs
or MPPs in recipients of Rictor-deficient or control cells
16 weeks after transplantation (Figure 5L). We also did not
observe significant differences in the reconstituting capacity
of Rictor-deficient and control bone marrow cells in secondary
recipients (Figures 5M and 5N). Rictor is therefore not neces-
sary for HSC maintenance or function in normal adult mice,
though its absence may lead to modest deficits in lymphoid
reconstitution.Cell Stem Cell 11, 415–428, SRictor Is Necessary for Adult HSC
Proliferation and Depletion after
Pten Deletion
We administered pIpC to control, Mx1-
Cre; Ptenfl/fl, Mx1-Cre; Rictorfl/fl, and
Mx1-Cre; Ptenfl/fl; Rictorfl/fl mice 6 weeksafter birth and analyzed HSCs 2 weeks later. Since rapamycin
rescues the proliferation of Pten-deficient HSCs (Yilmaz et al.,
2006), we also administered rapamycin to some Mx1-Cre;
Ptenfl/fl mice and controls for 1 week prior to analysis. Rapamy-
cin did not appear to affect mTORC2 function in primitive hema-
topoietic progenitors as it did not affect AKT phosphorylation at
Ser473 in Pten-deficient LSK cells in vivo (7 days at 4mg/kg/day;
Figure 6A), or after 30 min of culture in rapamycin-containing
medium (100 nm; Figure 6B). In contrast, Rictor deletion may
modestly reduce mTORC1 activation as phosphorylated S6
levels were modestly reduced in Rictor-deficient as compared
to control LSK cells and phosphorylated S6 levels were reduced
as a fraction of total S6 levels in Mx1-Cre; Ptenfl/fl; Rictorfl/fl LSKeptember 7, 2012 ª2012 Elsevier Inc. 423
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Temporal Changes in Signaling in Stem Cellscells relative toMx1-Cre; Ptenfl/fl LSK cells (Figure 4N). A decline
in mTORC1 signaling after Rictor deletion may be expected as
mTORC2 signaling increases AKT signaling and therefore
mTORC1 activation (Guertin and Sabatini, 2007; Guertin et al.,
2009). In primitive hematopoietic progenitors rapamycin thus
appears to reduce mTORC1 function without affecting mTORC2
while Rictor deletion appears to eliminate mTORC2 function
while modestly reducing mTORC1 function.
Pten deletion significantly increased the fraction of HSCs in
S/G2/M phases of the cell cycle and rapamycin rescued this
effect (Figure 6C). Rictor deletion by itself did not significantly
affect the frequency of HSCs in S/G2/M phases of the cell cycle
but did significantly reduce the fraction of Pten-deficient HSCs in
S/G2/M phases of the cell cycle (Figure 6C). Treating Pten/Rictor
compound mutant mice with rapamycin did not further reduce
HSC proliferation. Rictor deletion also significantly reduced the
mobilization of Pten-deficient HSCs but rapamycin had no effect
(Figure 6D). Taken together this suggests that mTORC2 medi-
ates the effects of Pten deletion on HSC function through
mTORC1-dependent and mTORC1-independent mechanisms,
consistent with studies in other cell types (Guertin and Sabatini,
2007).
Rapamycin treatment, but not Rictor deletion, reduced the
mobilization of wild-type HSCs from the bone marrow to the
spleen after cyclophosphamide/G-CSF treatment (Figures 6E
and 6F). This suggests that mTORC1, not mTORC2, is the
major mediator of HSC proliferation under physiological condi-
tions in wild-type mice. This conclusion is consistent with the
paucity of Ser473 phosphorylation of AKT (an mTORC2 site;
Guertin et al., 2006) in fetal, neonatal, and cyclophospha-
mide/G-CSF mobilized HSCs (Figures 1D–1G) and with the
lack of effect of Rictor deletion on HSC frequency or prolifera-
tion (Figure 5). Pten deletion therefore induces the proliferation
and mobilization of HSCs through mTORC2-dependent mech-
anisms that do not mimic physiological HSC self-renewal
mechanisms.
To test if Rictor is necessary for the depletion of Pten-deficient
HSCs, we administered pIpC to 6-week-old control, Mx1-Cre;
Ptenfl/fl, Mx1-Cre; Rictorfl/fl, and Mx1-Cre; Ptenfl/fl; Rictorfl/fl
mice, then isolated HSCs 2 weeks later. We transplanted 10
CD45.2+ HSCs from donor mice into irradiated CD45.1+ mice
along with 300,000 wild-type CD45.1+ bone marrow cells. As ex-
pected, control HSCs gave high levels of long-term multilineage
reconstitution in all recipient mice and Pten-deficient HSCs gave
only transient multilineage reconstitution in all recipient mice
(Figures 6G–6K). Rictor-deficient HSCs gave long-term multili-
neage reconstitution in 3 of 12 recipient mice. Most of the re-
maining mice had long-term myeloid reconstitution, suggesting
that HSC activity was maintained in these mice, but they did
not necessarily have long-term lymphoid reconstitution (Figures
6G–6K). In contrast to Pten-deficient HSCs, Pten; Rictor
compound mutant HSCs gave long-term multilineage reconsti-
tution in almost all recipient mice with levels of donor myeloid
and T cell reconstitution that were at least as high as from control
HSCs (Figures 6G–6K). Pten; Rictor compound mutant HSCs
gave much lower levels of B lineage reconstitution than control
HSCs (Figure 6I), suggesting that Rictor deficiency largely
rescued the function of Pten-deficient HSCs but did not rescue
the function of Pten-deficient B lineage progenitors.424 Cell Stem Cell 11, 415–428, September 7, 2012 ª2012 Elsevier ISecondary recipients of Rictor-deficient cells exhibited long-
termmultilineage reconstitution in most mice, but levels of donor
cells were significantly lower than from control cells (Figures 6L–
6P). Secondary recipients of Mx1-Cre; Ptenfl/fl; Rictorfl/fl cells
also exhibited long-term multilineage reconstitution in most
recipient mice, with levels of donor cell reconstitution that were
intermediate between control and Rictor-deficient cells (Figures
6L–6P). Rictor deficiency therefore substantially rescued HSC
function after Pten deletion, enabling Pten deficient HSCs to
give long-term multilineage reconstitution of primary and
secondary recipient mice.
Rictor Is also Required for Leukemogenesis following
Pten Deletion
To determine whetherRictor is necessary for the development of
myeloproliferative disorder and leukemia followingPten deletion,
we administered pIpC to control, Mx1-Cre; Ptenfl/fl, Mx1-Cre;
Rictorfl/fl, and Mx1-Cre; Ptenfl/fl; Rictorfl/fl mice 6 weeks after
birth. We administered rapamycin for 7 days to some of these
mice. We harvested spleens 2 weeks after the initial pIpC treat-
ment. Spleens from Mx1-Cre; Ptenfl/fl mice were significantly
more cellular than spleens of other genotypes, as expected (Fig-
ure 7A). Spleens fromMx1-Cre; Ptenfl/fl; Rictorfl/fl and rapamycin-
treated Mx1-Cre; Ptenfl/fl mice were also significantly more
cellular than control spleens, but they were significantly less
cellular than spleens fromMx1-Cre; Ptenfl/flmice (Figure 7A). Ra-
pamycin in Mx1-Cre; Ptenfl/fl; Rictorfl/fl mice further reduced
spleen cellularity, rendering it similar to control spleens (Fig-
ure 7A). Rictor deletion and rapamycin treatment therefore addi-
tively reduce the severity of myeloproliferative disorder afterPten
deletion, suggesting thatmTORC1 andmTORC2both contribute
to this phenotype (Figure 7A). Nonetheless, extramedullary
hematopoiesis was still histologically evident in the spleens of ra-
pamycin-treated Mx1-Cre; Ptenfl/fl; Rictorfl/fl mice, suggesting
that rapamycin treatment and Rictor deletion did not completely
eliminate the myeloproliferative disorder (Figure S5).
To determine whether Rictor is necessary for progression to
acute leukemia following Pten deletion, we administered pIpC
to control, Mx1-Cre; Ptenfl/fl, Mx1-Cre; Ptenfl/+; Rictorfl/fl, Mx1-
Cre; Ptenfl/fl; Rictorfl/+, and Mx1-Cre; Ptenfl/fl; Rictorfl/fl mice
6 weeks after birth. All control and Mx1-Cre; Ptenfl/+; Rictorfl/fl
mice survived for the 115 day duration of the experiment (n =
7–11 mice/treatment; Figure 7B) with no signs of leukemia
(Figures 7F and 7J). All Mx1-Cre; Ptenfl/fl mice died by 77 days
after pIpC treatment (n = 8, range 14–77 days; Figure 7B) with
T-ALL (Figures 7G and 7K). All but one Mx1-Cre; Ptenfl/fl;
Rictorfl/+ mouse died by 80 days after pIpC treatment (n = 6,
range 26–115 days; Figure 7B) with T-ALL (data not shown).
Nine of twelve Mx1-Cre; Ptenfl/fl; Rictorfl/fl mice survived for
115 days (n = 12, range 19–115 days; Figure 7B) with myelopro-
liferative disorder in the spleen (Figure 7I) but no evidence of
T-ALL in the spleen or thymus (Figures 7I and 7M). Spleens
from Mx1-Cre; Ptenfl/fl; Rictorfl/fl mice were larger than spleens
from control or Mx1-Cre; Ptenfl/+; Rictorfl/fl mice (Figures 7C
and 7E). In contrast, thymuses from Mx1-Cre; Ptenfl/fl; Rictorfl/fl
mice were not enlarged relative to control or Mx1-Cre; Ptenfl/+;
Rictorfl/fl mice (Figures 7D and 7E). The Mx1-Cre; Ptenfl/fl;
Rictorfl/fl mice that died in this experiment did have T-ALL.
However, genotyping of genomic DNA from one T-ALL revealednc.
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Figure 7. Rictor Deficiency Reduced the Severity of Myeloproliferative Disorder and the Incidence of Leukemia after Pten Deletion
(A) Two weeks after pIpC treatment in adult mice, spleen cellularity increased significantly inMx1-Cre; Ptenfl/fl (PtenD/D) mice due to myeloproliferative disorder,
and this increase was significantly attenuated by Rictor deletion and rapamycin treatment (n = 5–10 mice/genotype, *p < 0.05; **p < 0.01; ***p < 0.001; N.S., not
significant [p > 0.05]).
(B) Kaplan-Meier survival curves after pIpC treatment showed that Rictor deletion significantly increased the survival of Pten-deleted mice (p < 0.001 relative to
PtenD/D; Rictor+/+ mice by log-rank test).
(C–E) Spleen and thymus sizes of mice from the same experiment 16 weeks after pIpC treatment (E; n = 5–7 mice/genotype, ***p < 0.001).
(F–M) A myeloproliferative disorder was evident in the spleens of PtenD/D; RictorD/D mice (I) but not control or PtenD/+; RictorD/D mice (F and H). T-ALL was
observed in the spleens of PtenD/D; Rictor+/+ mice (G, arrows) but not in the spleens of other genotypes. Thymuses of control (J), Pten+/+; RictorD/D (L), and
PtenD/D; RictorD/D (M) mice did not have T-ALL, in contrast to PtenD/D; Rictor+/+ thymuses (K).
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Temporal Changes in Signaling in Stem Cellsthat the floxed Rictor allele had not been deleted in this clone of
leukemia cells (data not shown). Rictor deletion thus significantly
reduced the incidence of leukemia in mice after Pten deletion.
PTEN is therefore required in adult, but not neonatal, hematopoi-
etic cells to suppress leukemia by reducing mTORC2 activation.Cell SDISCUSSION
The PI3-kinase pathway regulates adult HSC proliferation
and leukemogenesis. Akt1/2 deletion increases adult HSC
quiescence (Juntilla et al., 2010). Increased activation of thetem Cell 11, 415–428, September 7, 2012 ª2012 Elsevier Inc. 425
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Temporal Changes in Signaling in Stem CellsPI3-kinase pathway by Pten deletion, overexpression of Akt1, or
Tsc2 deletion promotes adult HSC proliferation and HSC deple-
tion (Yilmaz et al., 2006; Zhang et al., 2006; Chen et al., 2008;
Gan et al., 2008; Kharas et al., 2010; Lee et al., 2010). However,
fetal and neonatal HSCs/MPPs did not exhibit increased AKT
phosphorylation relative to adult HSCs/MPPs even though
more fetal/neonatal HSCs/MPPs were in cycle (Figures 1B–1E).
This suggests that while increased PI3-kinase pathway activa-
tion by Pten deletion can drive adult HSCs into cycle, sustained
AKT phosphorylation is not observed in HSCs that divide
frequently under physiological conditions. Consistent with this,
Rictor deletion reduced AKT phosphorylation (Figures 4M and
4N) but had only modest effects on the maintenance and func-
tion of HSCs (Figure 5). Nonetheless, Rictor was required for
increased HSC proliferation (Figure 6C), HSC depletion (Figures
6G–6K), and leukemogenesis (Figure 7) following Pten deletion.
PTEN is therefore required in adult, but not neonatal, hematopoi-
etic cells to maintain HSCs and to suppress leukemia by
reducing mTORC2 activation. Rictor deletion also reduces the
incidence of prostate cancer after Pten deletion, while having
little effect on wild-type prostate epithelium (Guertin et al., 2009).
Our data indicate that mTORC1 and mTORC2 have distinct
functions in dividing HSCs. While Rictor-deficient HSCs gave
long-term multilineage reconstitution of irradiated mice (Fig-
ure 5), Kalaitzidis et al. (2012) found that Raptor-deficient
HSCs were unable to reconstitute irradiated mice. Fetal HSCs
and cyclophosphamide/G-CSF mobilized HSCs exhibited
increased mTORC1, but not mTORC2, activation relative to
quiescent adult HSCs (Figures 1D and 1G). Rapamycin treat-
ment, but not Rictor deletion, reduced HSC mobilization after
cyclophosphamide/G-CSF treatment (Figure 6F). These results
demonstrate that mTORC1 is more important than mTORC2
for the proliferation of HSCs under physiological conditions.
In contrast, both mTORC1 and mTORC2 were activated by
Pten deletion (Figure 1D). Rictor deletion, but not rapamycin
treatment, reduced HSC mobilization after Pten deletion (Fig-
ure 6D). Rapamycin treatment and Rictor deletion both reduced
HSC proliferation after Pten deletion (Figure 6C) and additively
reduced the severity of myeloproliferative disorder following
Pten deletion (Figure 7A). These results demonstrate that
mTORC2 is a major mediator of the effects of Pten deletion on
hematopoietic cells, and that mTORC2 likely signals through
mTORC1-dependent and mTORC1-independent pathways.
Therefore both mTORC1 and mTORC2 contribute to the hema-
topoietic phenotypes observed after Pten deletion, consistent
with our previously published results (Yilmaz et al., 2006; Lee
et al., 2010) and the results in Kalaitzidis et al. (2012).
Our data indicate that temporal changes in the regulation of
the PI3-kinase pathway lead to temporal changes in the mecha-
nisms that regulate HSC function and leukemogenesis. This
likely explains why conditional deletion of Pten from fetal hema-
topoietic cells using VE-Cadherin-Cre does not lead to the devel-
opment of leukemia until around 8 weeks after birth (Guo et al.,
2008). It is not yet clear why Pten deletion increases PI3-kinase
pathway activation in adult, but not neonatal, HSCs. Neonatal
HSCs were capable of activating the PI3-kinase pathway when
cultured (Figure 4D), but exhibited a cell-autonomous difference
relative to adult HSCs in their dependence upon PTEN in trans-
plantation assays (Figures 2E–2H). We have identified a number426 Cell Stem Cell 11, 415–428, September 7, 2012 ª2012 Elsevier Iof gene products that are differentially expressed between
neonatal and adult HSCs and that could potentially influence
PI3-kinase pathway signaling (Figure S2). However, much
more work will be required to assess their functions in neonatal
and adult HSCs.
Since neonatal HSCs and other hematopoietic cells can
harbor mutations in Pten and p53 without transforming into
leukemia until adulthood, our data suggest that mutated cells
may persist for years in children before a change in develop-
mental context renders these mutations competent to induce
leukemia. Prolonged persistence of cells with leukemogenic
mutations has been documented in human pediatric leukemia
patients (Wiemels et al., 1999a, 1999b). In the past, this latency
has been attributed to the time necessary to accrue secondary
mutations. However, our data suggest an additional explanation:
that some of these mutations were not competent to cause
leukemia until the blood cells matured into a susceptible devel-
opmental context. This could explain why T-ALL presents
more commonly in older rather than younger children. Our find-
ings raise the possibility of reprogramming therapies that are
analogous to differentiation therapies. Reprogramming of adult
hematopoietic cells to a fetal or neonatal identity (Kim et al.,
2007; He et al., 2011) could blunt the effects of leukemogenic
mutations that require an adult developmental context to induce
neoplastic proliferation.
EXPERIMENTAL PROCEDURES
Mouse Strains and pIpC Injections
Ptenfl/flmice,Mx1-Cremice, and p53/mice have been previously described
(Jacks et al., 1994; Ku¨hn et al., 1995; Groszer et al., 2006). These mice were all
backcrossed for at least eight generations onto a C57BL/6Ka-Thy-1.1
(CD45.2) background. See the Supplemental Experimental Procedures for
a description of the generation of Rictorfl allele. Expression of Mx1-Cre was
induced by a single subcutaneous injection of pIpC (Amersham) in neonatal
mice at P2 or by three intraperitoneal injections over 6 days in adult mice
beginning 6 weeks after birth. pIpC dose was determined empirically for
each lot so that >95% of HSC colonies exhibited complete recombination of
the Ptenfl/fl and Rictorfl/fl alleles (Figures S1 and S4). Neonatal mice received
1–2 mg/dose, depending on pIpC lot. Adult mice received 10 mg/dose. All
mice were housed in the Unit for Laboratory Animal Medicine at the University
of Michigan (UM), where these studies were initiated, or at the Animal
Resource Center at UT-Southwestern Medical Center, where the studies
were completed. All animal procedures were approved by the UM and UT
Southwestern Committees on the Use and Care of Animals.
Flow Cytometry and Isolation of HSCs
Bone marrow cells and splenocytes were obtained, stained, and analyzed by
flow cytometry as previously described (Lee et al., 2010; Nakada et al., 2010).
Antibodies and detailedmethods are in the Supplemental Experimental Proce-
dures (Table S1).
BrdU Incorporation and Cell Cycle Analysis
BrdU (Sigma; diluted to 5–10 mg/ml in PBS) was administered by IP injections
(100 mg/kg/dose) given every 8 hr beginning 24 hr prior to bone marrow
harvest. HSCs were stained and enriched by c-kit selection as described in
the Supplemental Experimental Procedures, and BrdU incorporation was
measured by flow cytometry using the APC BrdU Flow Kit (BD Biosciences).
For cell cycle analysis, HSCs were stained with antibodies against CD150,
CD48, lineage markers, c-kit, and Sca-1. c-kit+ cells were enriched by selec-
tion with paramagnetic beads (Miltenyi Biotec, Auburn, CA). The enriched cells
were fixed and permeablized with cytofix/cytoperm buffer (BD Biosciences)
then washed in staining medium, and stained with DAPI (20 mg/ml). HSCs
were analyzed by flow cytometry. For analysis of AKT phosphorylation innc.
Cell Stem Cell
Temporal Changes in Signaling in Stem CellsHSCs/MPPs in different phases of the cell cycle (Figure 1E), Vybrant DyeCycle
Violet Stain (Invitrogen) was used to analyze DNA content while preserving cell
viability. A detailed protocol is provided in the Supplemental Experimental
Procedures.
Western Blots
Twenty or thirty thousand CD48LSK cells were sorted and then resorted (to
ensure purity) into Trichoracetic acid (TCA), and the volume was adjusted to
a final concentration of 10% TCA. LSK cells were sometimes incubated at
37C in Iscove’s medium plus 2% fetal bovine serum for 30min prior to protein
extraction in 10% TCA. Extracts were incubated on ice for at least 15 min and
centrifuged at 16,100 3 g at 4C for 10 min. Precipitates were washed in
acetone twice and dried. The pellets were solubilized in 9M urea, 2% Triton
X-100, and 1% DTT. LDS loading buffer (Invitrogen) was added and the pellet
was heated at 70C for 10 min. Samples were separated on Bis-Tris polyacryl-
amide gels (Invitrogen) and transferred to PVDF membrane (Millipore). Anti-
bodies are listed in the Supplemental Experimental Procedures (Table S1).
Western blotting was performed according to the protocol from Cell Signaling
Technologies, and blots were developed with the SuperSignal West Femto
chemiluminescence kit (Thermo Scientific). Blots were stripped (1% SDS,
25 mM glycine [pH 2]) prior to reprobing.
Long-Term Reconstitution Assays
Competitive reconstitution experiments were performed as previously
described (Lee et al., 2010; Nakada et al., 2010). A complete description of
long-term reconstitution assays is provided in the Supplemental Experimental
Procedures.
Survival and Leukemia Analysis
After administering pIpC tomice as described above, themice weremonitored
daily andmorbid mice were euthanized. Spleen and thymus tissues were fixed
in buffered 10% formalin and embedded in paraffin for sectioning and hema-
toxylin and eosin (H&E) staining. Bone marrow cytospin specimens were
Wright-Giemsa stained (Sigma). J.A.M., a pediatric hematologist, reviewed
all slides and bone marrow specimens.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes five figures, three tables, and
Supplemental Experimental Procedures and can be found with this article on-
line at http://dx.doi.org/10.1016/j.stem.2012.05.026.
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